|
 |
|
 |
|
|
Aphthasol® 5% Paste (amlexanox) |
|
|
|
|
|
|
|
Aphthous
Ulcers-The Disease: |
|
|
|
|
|
|
|
Recurrent aphthous
ulcers (RAU) or stomatitis (RAS) is characterized by painful,
recurring ulcerations of the oral mucosa. It is the most
common oral ulcerative disease in human beings yet a principal
etiology has yet to be discovered. It is estimated that there
are 15 million patients in the USA who suffer from recurrent
aphthous ulcers of which 5 million are chronic sufferers.
There is a significant body of evidence suggesting an
immunologic mechanism as a cause of RAU. Recurrence may be
precipitated by trauma, hormonal changes, physical or psychic
stress and chemical irritants. Allergy and genetic factors
have been associated with the disease. Of those factors which
can potentially exacerbate RAU, several studies seem to
support the association of minor mucosal trauma with ulcer
onset in susceptible individuals. While the specific nature of
the disease remains unknown, current evidence suggests
aphthous stomatitis is a non-infectious inflammatory mucosal
disease. Recurrences can last anywhere from 4 to 30 days, with
most episodes lasting 7 to 10 days. |
|
|
|
|
|
|
|
Aphthasol® 5%
Paste (amlexanox)-The Product: |
|
|
|
|
|
|
|
Aphthasol®
contains 5% amlexanox in an adhesive oral paste. Aphthasol® is
FDA approved and indicated for the treatment of aphthous
ulcers in people with normal immune systems. |
|
|
|
|
|
|
|
Aphthasol® 5%
Paste (amlexanox)-Advantages: |
|
|
|
|
|
|
|
Accelerates
healing of Aphthous Ulcer |
|
|
|
|
|
|
|
- 39% faster
rate of ulcer reduction
- Shorter
median time to treat ulcers
|
|
|
|
Accelerates
Complete Resolution of Pain |
|
|
|
|
|
|
|
Effective for
Treatment of Aphthous Ulcers |
|
|
|
|
|
|
|
The inactive
ingredients of the Aphthasol® 5% Paste are all listed on the
FDA Inactive Ingredients List and are classified as GRAS
(generally regarded as safe). |
|
|
|
|
|
|
|
“The beneficial
effect of 5% amlexanox paste to accelerate the healing of
aphthous ulcers has been clearly and consistently demonstrated
in the four similarly designed vehicle-controlled, studies
described in this article." |
|
|
|
(Source: Oral Surg, Oral Med, Oral Pathol, Oral Radio Endo.
1997; 83:222-30) |
|
|
|
|
|
|
|
|
|